MIST Milestone Pharmaceuticals

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the , to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the , to be held April 7-9th in Berlin, Germany. The presentations will be available following the embargo at .

ACC Presentation Details:

 
Oral Presentation Title: Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303)
Presenter: James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time: Monday, April 8, 2024, 11:36 – 11:46 a.m. EDT
   
Poster Presentation Title: Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms
Presenter: James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time: Sunday, April 7, 2024, 12:15 – 1:00 p.m. EDT
   
EHRA Presentation Details:
   
Poster Presentation Title: Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes
Presenter: David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc.
Date and time: Sunday, April 7, 2024, 10:15 a.m. CET
   

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications

Investor Relations

Chris Calabrese,  

Kevin Gardner,

 



EN
01/04/2024

Underlying

MISTMilestone Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Milestone Pharmaceuticals

 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel a...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal spray MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as , the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular ...

February 10, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listi...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 419,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees....

February 3, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (e...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured patientsLaunch supported by comprehensive patient assistance program offering benefits verification and reimbursement support MONTREAL and CHARLOTTE, N.C., Jan. 26, 2026 (GLOB...

January 26, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorizat...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency  European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medici...

January 6, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTT...

December 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch